**Table 1**. Baseline demographic, clinical characteristics and lung function measures of SSc patients with and without PF.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **SSc with PF**  **n=41** | | **SSc without PF**  **n=94** | | ***p*** |
| FVC, % predicted | 81.7 | (14.3) | 90.3 | (18.7) | <0.001 |
| DLCO, % predicted | 52.6 | (15.7) | 67.1 | (17) | <0.001 |
| Disease duration | 3 | [1-7.25] | 4 | [1-9.5] | 0.787 |
| dcSSc | 27 | (65.9%) | 23 | (24.5%) | <0.001 |
| Sclerodactyly | 32 | (78%) | 15 | (74.3%) | 0.800 |
| Puffyfingers | 4 | (9.8%) | 11 | (11.7%) | 0.480 |
| Synovitis | 0 |  | 11 | (11.7%) | 0.011 |
| Calcinosis cutis | 2 | (5.3%) | 3 | (3.5%) | 0.492 |
| Telengiectasia | 23 | (56%) | 52 | (55.3%) | 0.823 |
| Digital ulcer | 16 | (39%) | 22 | (23.4%) | 0.072 |
| Pitting scar | 19 | (46.3%) | 32 | (34%) | 0.199 |
| PAH | 4 | (9.8%) | 4 | (4.3%) | 0.204 |
| ANA positive | 40 | (97.6%) | 93 | (98.9%) | 0.517 |
| Anti-Scl-70 positive | 22 | (53.7%) | 26 | (27.7%) | <0.001 |
| ACA positive | 10 | (24.4%) | 54 | (57.4%) | 0.004 |
| PA diameter | 27.8 | (4.44) | 23.9 | (4.26) | <0.001 |
| PA dilatation | 14 | (34.1) | 11 | (11.7%) | 0.002 |

PF, pulmonary fibrosis; dcSSc, diffuse cutaneous systemic sclerosis; PAH, pulmonary artery hypertension; PA, pulmonary artery; ANA, antinuclear antibody; ACA, anticentromere antibody

**Table 2**.Comparison of HRCT measurements between SSc patients with PF, without PF and control group,

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **SSc with PF**  **n=41** | | **SSc without PF**  **n=94** | | **Control**  **n=38** | | ***p*** |
| Right lung density, HU | -740 | (80) | -806 | (65.2) | -801 | (59.3) | <0.001 |
| Left lung density, HU | -720 | (74.4) | -789 | (64.5) | -798 | (65.4) | <0.001 |
| Right lung volume, mL | 1616 | (460) | 1906 | (441) | 1809 | (481) | 0.006 |
| Left lung volume, mL | 1394 | (435) | 1702 | (432) | 1525 | (447) | 0.002 |

PF, pulmonary fibrosis; HU, Hounsfield units

**Table 3**.Comparison of HRCT measurements between dcSSc patients without PF, lcSSc patients without PF and control group,

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **dcSSc without PF**  **n=23** | | **lcSSc without PF**  **n=71** | | **Control**  **n=38** | | ***p*** |
| Right lung density, HU | -764 | (70.1) | -820 | (57.7) | -801 | (59.3) | 0.002 |
| Left lung density, HU | -738 | (62.1) | -805 | (56.7) | -798 | (65.4) | <0.001 |
| Right lung volume, mL | 1755 | (294) | 1956 | (470) | 1809 | (481) | 0.045 |
| Left lung volume, mL | 1594 | (299) | 1738 | (463) | 1525 | (447) | 0.044 |

PF, pulmonary fibrosis; HU, Hounsfield units

**Table 4**.Comparison of HRCT measurements between the SSc patients who did and did not develop PF during follow-up.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **No PF**  **n=42** | | **PF**  **n=16** | | ***p*** |
| Right lung density, HU | -808 | (65.2) | -753 | (75.6) | 0.018 |
| Left lung density, HU | -787 | (63.4) | -734 | (72.7) | 0.014 |
| Right lung volume, mL | 1867 | (466) | 1714 | (283) | 0.164 |
| Left lung volume, mL | 1629 | (391) | 1546 | (319) | 0.503 |

PF, pulmonary fibrosis; HU,Hounsfield units

**Table 5**. Correlation between FVC and DLCO and lung measures in patients with and without pulmonary fibrosis.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **SSc without PF**  **n=94** | | | | **SSc with PF**  **n=41** | | | |
|  | **FVC** | | **DLCO** | | **FVC** | | **DLCO** | |
|  | *r* | *p* | *r* | *p* | *r* | *p* | *r* | *p* |
| Right lung density, HU | -0.107 | 0.351 | -0.050 | 0.670 | -0.601 | 0.001\* | -0.487 | 0.012\* |
| Left lung density, HU | -0.230 | 0.043\* | -0.153 | 0.190 | -0.507 | 0.005\* | -0.393 | 0.047\* |
| Right lung volume, mL | 0.331 | 0.003\* | 0.185 | 0.113 | 0.358 | 0.057 | 0.338 | 0.091 |
| Left lung volume, mL | 0.299 | 0.008\* | 0.248 | 0.032\* | 0.500 | 0.006\* | 0.402 | 0.042\* |

PF, pulmonary fibrosis; HU, Hounsfield units. \*p<0.05